Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSONYSE:ELMDNYSE:NVRONASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$1.00$1.07$0.70▼$1.61$54.68M0.78144,967 shs105,471 shsELMDElectromed$23.86+2.2%$28.97$13.74▼$35.56$204.17M0.4166,765 shs82,256 shsNVRONevro$5.85+0.1%$5.56$3.17▼$14.43$224.28M0.94736,277 shs640,909 shsPROFProfound Medical$5.82-3.8%$6.78$4.75▼$11.42$174.83M0.7853,679 shs69,679 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents0.00%+1.68%-5.66%+11.11%+5.26%ELMDElectromed0.00%-5.62%-13.68%-22.61%+44.52%NVRONevro0.00%+1.21%+2.10%+57.12%-59.52%PROFProfound Medical0.00%-11.16%-12.70%-14.18%-29.07%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents2.0511 of 5 stars3.53.00.00.02.40.00.6ELMDElectromed1.2296 of 5 stars2.00.00.00.03.92.50.0NVRONevro0.9098 of 5 stars1.05.00.00.01.31.70.6PROFProfound Medical2.2897 of 5 stars3.72.00.00.02.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$4.67366.67% UpsideELMDElectromed 4.00Strong Buy$38.0059.26% UpsideNVRONevro 1.92Reduce$6.439.92% UpsidePROFProfound Medical 3.33Buy$14.25144.85% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, NVRO, ELMD, and PROF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/20/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.002/19/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/10/2025NVRONevroJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Hold$4.50 ➝ $5.852/7/2025NVRONevroCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$4.00 ➝ $5.852/7/2025NVRONevroPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$6.00 ➝ $5.851/13/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.001/3/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$33.79M1.62N/AN/A$0.52 per share1.92ELMDElectromed$59.63M3.42$0.58 per share41.36$5.10 per share4.68NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72PROFProfound Medical$10.68M16.37N/AN/A$1.28 per share4.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$28.51M-$0.36N/AN/AN/A-49.47%-118.54%-42.31%3/31/2025 (Estimated)ELMDElectromed$5.15M$0.7531.81∞N/A11.34%15.71%13.37%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%5/6/2025 (Estimated)PROFProfound Medical-$28.57M-$1.12N/AN/AN/A-349.41%-85.22%-64.87%5/8/2025 (Estimated)Latest CTSO, NVRO, ELMD, and PROF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 millionN/A3/6/2025Q4 2024PROFProfound Medical-$0.31-$0.20+$0.11-$0.20$5.92 million$4.18 million3/4/2025Q4 2024NVRONevro-$0.79-$0.64+$0.15-$1.41$102.61 million$105.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents1.061.971.58ELMDElectromedN/A5.104.74NVRONevro0.675.023.76PROFProfound Medical0.116.125.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%ELMDElectromed40.82%NVRONevro95.52%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents6.60%ELMDElectromed14.00%NVRONevro3.20%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22054.68 million51.07 millionOptionableELMDElectromed1608.56 million7.36 millionOptionableNVRONevro1,21538.37 million36.27 millionOptionablePROFProfound Medical15030.04 million29.58 millionOptionableCTSO, NVRO, ELMD, and PROF HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMarch 31 at 2:45 PM | prnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities InvestigationMarch 31 at 10:00 AM | accessnewswire.comIs TULSA-PRO Covered by Medicare?March 30 at 11:14 PM | aol.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the InvestigationMarch 30 at 10:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the InvestigationMarch 28 at 10:00 AM | accessnewswire.comKuriakose: Slashed medical research funding has put lives at riskMarch 27, 2025 | detroitnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMarch 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities InvestigationMarch 27, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMarch 27, 2025 | accessnewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities lawsMarch 26, 2025 | investing.comWolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities lawsMarch 26, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach OutMarch 26, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach OutMarch 25, 2025 | accessnewswire.comSave the Date: Profound Medical to Host Investor Event at AUA 2025March 25, 2025 | financialpost.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMarch 24, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to ConnectMarch 24, 2025 | accessnewswire.comRaymond James Financial Inc. Acquires Shares of 875,709 Profound Medical Corp. (NASDAQ:PROF)March 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMarch 23, 2025 | accessnewswire.comRosalind Advisors Inc. Has $5.20 Million Stake in Profound Medical Corp. (NASDAQ:PROF)March 23, 2025 | marketbeat.comMagnetar Financial LLC Makes New $3.83 Million Investment in Profound Medical Corp. (NASDAQ:PROF)March 22, 2025 | marketbeat.comPROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law FirmMarch 21, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, NVRO, ELMD, and PROF Company DescriptionsCytosorbents NASDAQ:CTSO$1.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.10 (+10.00%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Electromed NYSE:ELMD$23.86 +0.52 (+2.23%) Closing price 04:00 PM EasternExtended Trading$24.81 +0.95 (+3.98%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Nevro NYSE:NVRO$5.84 +0.01 (+0.09%) Closing price 03:59 PM EasternExtended Trading$5.85 +0.00 (+0.09%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Profound Medical NASDAQ:PROF$5.82 -0.24 (-3.88%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
